이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Interpace Biosciences 관리

관리 기준 확인 4/4

Interpace Biosciences' CEO는 Tom Burnell, Dec2020 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $ 678.41K, 64.2% 로 구성됩니다. 64.2% 급여 및 35.8% 보너스(회사 주식 및 옵션 포함). 는 $ 97.84K 가치에 해당하는 회사 주식의 1.87% 직접 소유합니다. 97.84K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 4.4 년입니다.

주요 정보

Tom Burnell

최고 경영자

US$678.4k

총 보상

CEO 급여 비율	64.2%
CEO 임기	3.5yrs
CEO 소유권	1.9%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

CEO 보상 분석

Tom Burnell 의 보수는 Interpace Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$1m
Dec 31 2023	US$678k	US$436k	US$1m
Sep 30 2023	n/a	n/a	-US$1m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$634k	US$434k	-US$6m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$588k	US$425k	-US$7m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$935k	US$35k	-US$29m

보상 대 시장: Tom 의 총 보상 ($USD 678.41K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Tom 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tom Burnell (61 yo)

3.5yrs

테뉴어

US$678,407

보상

Dr. Thomas W. Burnell, also known as Tom, Ph.D. serves as the President, Chief Executive Officer and Director at Interpace Biosciences, Inc. since December 01, 2020 and serves as its Chairman from February...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Burnell	President	3.5yrs	US$678.41k	1.87% $ 94.8k
Christopher McCarthy	Chief Financial Officer	1.2yrs	US$332.04k	0.70% $ 35.5k
Sydney Finkelstein	Chief Scientific Officer	no data	데이터 없음	데이터 없음
Jody Campbell	Chief Revenue Officer	2.3yrs	데이터 없음	데이터 없음
Nicole Massoll	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Patrick Kane	VP & Corporate Controller	15yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

경험이 풍부한 관리: IDXG 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Burnell	President	3.5yrs	US$678.41k	1.87% $ 94.8k
Joseph Keegan	Independent Director	8.4yrs	US$50.00k	0.040% $ 2.0k
Stephen Sullivan	Independent Director	19.8yrs	US$62.50k	0.056% $ 2.9k
Vijay Aggarwal	Independent Director	2.3yrs	US$50.00k	0% $ 0
Fortunato Rocca	Independent Director	4.4yrs	US$40.00k	0% $ 0

4.4yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: IDXG 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Interpace Biosciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board’s Regulatory Compliance Committee

Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director

Interpace Biosciences, Inc., Annual General Meeting, Nov 14, 2023

Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer

Interpace Biosciences, Inc., Annual General Meeting, Nov 10, 2022

Interpace Biosciences Announces Appointment of Vijay Aggarwa as New Director to the Board of Directors

Recent updates

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board’s Regulatory Compliance Committee

Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director

Interpace Biosciences, Inc., Annual General Meeting, Nov 14, 2023

Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer

Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Interpace Biosciences, Inc., Annual General Meeting, Nov 10, 2022

Interpace Biosciences, Inc. Announces New Clinical Validation Data

Flagship Biosciences, Inc. completed the acquisition of Interpace Pharma Solutions from Interpace Biosciences, Inc. (OTCPK:IDXG).

Interpace Biosciences, Inc. Announces New Clinical Validation Data for Thyroid Cancer Test Platform Published Online Within Thyroid®, the Leading Peer-Reviewed Journal for Original Research on Thyroid Cancer

Interpace Biosciences, Inc Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

Interpace Biosciences Announces Appointment of Vijay Aggarwa as New Director to the Board of Directors

Interpace Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $27.930299 million.

Interpace Biosciences, Inc. Provides Revenue Guidance for the Full Year 2021

Interpace Biosciences, Inc. Provides Revenue Guidance Second Quarter of Fiscal 2021

Interpace Biosciences, Inc. announced delayed annual 10-K filing

Interpace Biosciences, Inc. Provides Full Year Revenue Guidance for 2021

DiamiR, LLC entered into a definitive agreement to acquire a CLIA certified laboratory in New Haven of Interpace Biosciences, Inc. (OTCPK:IDXG).

Interpace Biosciences, Inc. Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Interpace Biosciences to Be Delisted from Nasdaq and to Commence Trading on OTCQX

Interpace Biosciences Announces Impending Delisting from Nasdaq

Interpace Biosciences, Inc. Announces CFO Changes

Interpace Biosciences, Inc. Announces Executive Changes

Interspace Biosciences trades high, appoints new finance chief

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Interpace Biosciences, Inc. Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida

Interpace Biosciences, Inc. to Report Q3, 2020 Results on Jan 21, 2021

Interpace Biosciences, Inc. Announces CEO Changes

Interpace Biosciences Receives Nasdaq Deficiency Notice

Interpace Biosciences, Inc. announced delayed 10-Q filing

Interpace Biosciences, Inc. Announces Results of Seminal Clinical Validation Study for Thyroid Assays

Interpace Biosciences Receives Notice from Listing Qualifications Staff on Nasdaq

Interpace Biosciences, Inc. announced delayed 10-Q filing

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령